Search hospitals > Iowa > Iowa City

Iowa City VA Health Care System, Iowa City, IA

Claim this profile
Iowa City, Iowa 52246
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Parotid Gland Cancer
Conducts research for Prostatic Neoplasm
77 reported clinical trials
7 medical researchers
Photo of Iowa City VA Health Care System, Iowa City, IA in Iowa CityPhoto of Iowa City VA Health Care System, Iowa City, IA in Iowa CityPhoto of Iowa City VA Health Care System, Iowa City, IA in Iowa City

Summary

Iowa City VA Health Care System, Iowa City, IA is a medical facility located in Iowa City, Iowa. This center is recognized for care of Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Parotid Gland Cancer, Prostatic Neoplasm and other specialties. Iowa City VA Health Care System, Iowa City, IA is involved with conducting 77 clinical trials across 119 conditions. There are 7 research doctors associated with this hospital, such as Chandrikha Chandrasekharan, MBBS, Diana Jalal, MD, David Katz, MD, and Marion L Sanders, MD.

Area of expertise

1Non-Small Cell Lung Cancer
Iowa City VA Health Care System, Iowa City, IA has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage I
Stage II
Stage III
2Lung Cancer
Iowa City VA Health Care System, Iowa City, IA has run 8 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage III

Top PIs

Clinical Trials running at Iowa City VA Health Care System, Iowa City, IA

Lung Cancer
Chronic Kidney Disease
Kidney Disorders
Non-Small Cell Lung Cancer
Atherosclerosis
Diabetic Kidney Disease
ALK Gene Rearrangement
Kidney Transplant
Incretin Hormones in Polycystic Ovary Syndrome
Prediabetes
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Iowa City VA Health Care System, Iowa City, IA?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security